Apollomics, Inc. (NASDAQ:APLM) Short Interest Up 86.5% in February

Apollomics, Inc. (NASDAQ:APLM) was the target of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 6,900 shares, an increase of 86.5% from the January 31st total of 3,700 shares. Approximately 0.9% of the shares of the company are short sold. Based on an average daily trading volume, of 46,400 shares, the short-interest ratio is presently 0.1 days.

Apollomics Trading Up 1.8 %

NASDAQ:APLM opened at $6.62 on Friday. Apollomics has a 1 year low of $6.20 and a 1 year high of $80.50. The firm’s fifty day simple moving average is $8.92 and its 200 day simple moving average is $11.06.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.